AAAAAA

   
Results: 1-18 |
Results: 18
Orally bioavailable farnesyltransferase inhibitors as anticancer agents intransgenic and xenograft models
Authors: Liu, M Bishop, WR Nielsen, LL Bryant, MS Kirschmeier, P
Citation: M. Liu et al., Orally bioavailable farnesyltransferase inhibitors as anticancer agents intransgenic and xenograft models, METH ENZYM, 333, 2001, pp. 306-318
In vivo prenylation analysis of Ras and Rho proteins
Authors: Kirschmeier, PT Whyte, D Wilson, O Bishop, WR Pai, JK
Citation: Pt. Kirschmeier et al., In vivo prenylation analysis of Ras and Rho proteins, METH ENZYM, 332, 2001, pp. 115-127
The farnesyl transferase inhibitor SCH 66336 induces a G(2) -> M or G(1) pause in sensitive human tumor cell lines
Authors: Ashar, HR James, L Gray, K Carr, D McGuirk, M Maxwell, E Black, S Armstrong, L Doll, RJ Taveras, AG Bishop, WR Kirschmeier, P
Citation: Hr. Ashar et al., The farnesyl transferase inhibitor SCH 66336 induces a G(2) -> M or G(1) pause in sensitive human tumor cell lines, EXP CELL RE, 262(1), 2001, pp. 17-27
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
Authors: Peters, DG Hoover, RR Gerlach, MJ Koh, EY Zhang, HY Choe, K Kirschmeier, P Bishop, WR Daley, GQ
Citation: Dg. Peters et al., Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia, BLOOD, 97(5), 2001, pp. 1404-1412
Tricyclic farnesyl protein transferase inhibitors - Antitumor activity andeffects on protein prenylation
Authors: Bishop, WR Pai, JJK Armstrong, L Dalton, MB Doll, RJ Taveras, A Njoroge, G Sinensky, M Zhang, F Liu, M Kirschmeier, P
Citation: Wr. Bishop et al., Tricyclic farnesyl protein transferase inhibitors - Antitumor activity andeffects on protein prenylation, CANC DRUG, 8, 2001, pp. 87-101
A farnesyl transferase inhibitor suppresses TPA-mediated skin tumor development without altering hyperplasia in the ras transgenic Tg.AC mouse
Authors: Trempus, CS Bishop, WR Njoroge, FG Boll, RJ Battalora, MS Mahler, JG Haseman, JK Tennant, RW
Citation: Cs. Trempus et al., A farnesyl transferase inhibitor suppresses TPA-mediated skin tumor development without altering hyperplasia in the ras transgenic Tg.AC mouse, MOL CARCINO, 27(1), 2000, pp. 24-33
Biological effects and mechanism of action of farnesyl transferase inhibitors
Authors: Ashar, HR Armstrong, L James, LJ Carr, DM Gray, K Taveras, A Doll, RJ Bishop, WR Kirschmeier, PT
Citation: Hr. Ashar et al., Biological effects and mechanism of action of farnesyl transferase inhibitors, CHEM RES T, 13(10), 2000, pp. 949-952
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo
Authors: Shi, B Yaremko, B Hajian, G Terracina, G Bishop, WR Liu, M Nielsen, LL
Citation: B. Shi et al., The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo, CANC CHEMOT, 46(5), 2000, pp. 387-393
Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
Authors: Ashar, HR James, L Gray, K Carr, D Black, S Armstrong, L Bishop, WR Kirschmeier, P
Citation: Hr. Ashar et al., Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules, J BIOL CHEM, 275(39), 2000, pp. 30451-30457
A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
Authors: Adjei, AA Erlichman, C Davis, JN Cutler, DL Sloan, JA Marks, RS Hanson, LJ Svingen, PA Atherton, P Bishop, WR Kirschmeier, P Kaufmann, SH
Citation: Aa. Adjei et al., A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity, CANCER RES, 60(7), 2000, pp. 1871-1877
Treatment of neoplastic meningitis with intrathecal temozolomide
Authors: Sampson, JH Archer, GE Villavicencio, AT McLendon, RE Friedman, AH Bishop, WR Bigner, DD Friedman, HS
Citation: Jh. Sampson et al., Treatment of neoplastic meningitis with intrathecal temozolomide, CLIN CANC R, 5(5), 1999, pp. 1183-1188
Analogues of 1-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo-[5,6]-cyclohepta[1,2-b]pyridin-11-yl)piperidine as inhibitors of farnesyl protein transferase
Authors: Afonso, A Weinstein, J Kelly, J Wolin, R Rosenblum, SB Connolly, M Guzi, T James, L Carr, D Patton, R Bishop, WR Kirshmeier, P Liu, M Heimark, L Chen, KJ Nomeir, AA
Citation: A. Afonso et al., Analogues of 1-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo-[5,6]-cyclohepta[1,2-b]pyridin-11-yl)piperidine as inhibitors of farnesyl protein transferase, BIO MED CH, 7(9), 1999, pp. 1845-1855
Atropisomeric trihalobenzocycloheptapyridine analogues provide stereoselective FPT inhibitors with antitumor activity
Authors: Njoroge, FG Vibulbhan, B Bishop, WR Kirschmeier, P Bryant, MS Nomeir, AA Liu, M Doll, RJ Girijavallabhan, VM Ganguly, AK
Citation: Fg. Njoroge et al., Atropisomeric trihalobenzocycloheptapyridine analogues provide stereoselective FPT inhibitors with antitumor activity, BIO MED CH, 7(5), 1999, pp. 861-867
Analogs of 4-(3-bromo-8-methyl-10-methoxy-6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-yl)-1-(4-pyridinylacetyl)piperidine N-oxide as inhibitors of farnesyl protein transferase
Authors: Afonso, A Kelly, J Weinstein, J James, L Bishop, WR
Citation: A. Afonso et al., Analogs of 4-(3-bromo-8-methyl-10-methoxy-6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-yl)-1-(4-pyridinylacetyl)piperidine N-oxide as inhibitors of farnesyl protein transferase, BIOORG MED, 9(13), 1999, pp. 1875-1880
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units
Authors: Petit, T Izbicka, E Lawrence, RA Bishop, WR Weitman, S Von Hoff, DD
Citation: T. Petit et al., Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units, ANN ONCOL, 10(4), 1999, pp. 449-453
Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice
Authors: Liu, M Bryant, MS Chen, JP Lee, SN Yaremko, B Li, ZJ Dell, J Lipari, P Malkowski, M Prioli, N Rossman, RR Korfmacher, WA Nomeir, AA Lin, CC Mallams, AK Doll, RJ Catino, JJ Girijavallabhan, VM Kirschmeier, P Bishop, WR
Citation: M. Liu et al., Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice, CANC CHEMOT, 43(1), 1999, pp. 50-58
Identification of pharmacokinetically stable 3,10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities
Authors: Taveras, AG Deskus, J Chao, JP Vaccaro, CJ Njoroge, FG Vibulbhan, B Pinto, P Remiszewski, S del Rosario, J Doll, RJ Alvarez, C Lalwani, T Mallams, AK Rossman, RR Afonso, A Girijavallabhan, VM Ganguly, AK Pramanik, B Heimark, L Bishop, WR Wang, L Kirschmeier, P James, L Carr, D Patton, R Bryant, MS Nomeir, AA Liu, M
Citation: Ag. Taveras et al., Identification of pharmacokinetically stable 3,10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities, J MED CHEM, 42(14), 1999, pp. 2651-2661
Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models
Authors: Nielsen, LL Shi, B Hajian, G Yaremko, B Lipari, P Ferrari, E Gurnani, M Malkowski, M Chen, JP Bishop, WR Liu, M
Citation: Ll. Nielsen et al., Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models, CANCER RES, 59(23), 1999, pp. 5896-5901
Risultati: 1-18 |